Related Experiment Video
Updated: Jun 7, 2026
A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
Published on: July 3, 2013
Using large-scale RNAi screens to identify novel drug targets for cancer
Jeroen H Nijwening1, Roderick L Beijersbergen
1Netherlands Cancer Institute, Division of Molecular Carcinogenesis and NKI Robotics and Screening Center, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands. r.beijersbergen@nki.nl
Abstract:
In recent years, the development and clinical implementation of targeted therapeutics have progressed significantly. The specific inhibition of components of signal transduction pathways controlling proliferation and survival has been a highly successful research strategy. However, cancer is a heterogeneous disease and, even within one type of cancer, different genetic alterations are associated with identical phenotypes. To advance the use of targeted therapeutics, it is not only essential to identify the crucial factors in the signal transduction networks that control cell proliferation and survival, but also to classify individual tumors according to genetic alterations that correlate with pathway activation. RNAi screening technologies have become established as an important strategy both to identify novel targets and to provide novel biomarkers that are crucial for the further development of personalized medicine. This feature review discusses different RNAi screening strategies and their contribution to the rapidly evolving field of targeted therapeutics.
Insights
RNA interference (RNAi) screening identifies novel targets and biomarkers for personalized cancer medicine. This approach aids in classifying tumors by genetic alterations, advancing targeted therapeutics for better patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Targeted therapeutics have advanced significantly, focusing on inhibiting signal transduction pathways for cancer treatment.
- Cancer's heterogeneity and genetic alterations underlying similar phenotypes pose challenges for effective targeted therapy.
- Identifying crucial factors in cell proliferation and survival pathways is essential for advancing personalized medicine.
Purpose of the Study:
- To review RNA interference (RNAi) screening strategies for identifying novel therapeutic targets and biomarkers in cancer.
- To discuss the role of RNAi screening in classifying tumors based on genetic alterations and pathway activation.
- To highlight the contribution of RNAi screening to the development of personalized medicine and targeted therapeutics.
Main Methods:
- Discussion of various RNA interference (RNAi) screening strategies.
- Analysis of how these screening technologies identify novel therapeutic targets.
- Examination of RNAi's role in discovering biomarkers for personalized medicine.
Main Results:
- RNAi screening is a powerful strategy for identifying crucial components in signal transduction pathways.
- These technologies provide essential biomarkers for classifying tumors and guiding personalized treatment strategies.
- RNAi screening contributes significantly to the advancement of targeted therapeutics.
Conclusions:
- RNA interference (RNAi) screening is vital for identifying novel drug targets and predictive biomarkers in oncology.
- Classifying tumors by genetic alterations using RNAi facilitates the development of effective personalized medicine.
- RNAi screening technologies are crucial for the future of targeted cancer therapeutics.
More Related Videos
09:33Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor
Published on: August 25, 2023
07:48Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
Published on: December 26, 2016
Related Concept Videos
02:46Genetic Screens
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which result in visible changes...
02:15Experimental RNAi